Please provide your email address to receive an email when new articles are posted on . “Elevated [IOP] is one of the major risk factors for development and progression of POAG [primary open-angle ...

Please provide your email address to receive an email when new articles are posted on . Combined cataract surgery with iStent inject significantly reduced medication burden in patients with glaucoma.

WILMINGTON, NC (WECT) - A procedure for those with Glaucoma is making it easier to manage the degenerative eye condition on a day-to-day basis. Health officials say glaucoma is the second leading ...

Multiple 5-, 6-, 7- and 8-Year Real-World Studies Published, Demonstrating Leading Efficacy & Safety Across the Entire Glaucoma Disease Spectrum SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos ...

While Both iStent and iStent inject Showed Significant IOP and Medication Reduction in Combo-Cataract Procedures at 1 Year Postoperative, iStent inject Achieved Greater Absolute IOP Declines with 93% ...

CHERRY HILL, N.J. (WPVI) -- A new procedure is helping to preserve vision for some people with glaucoma. Glaucoma is a silent thief, affecting 3 million Americans, slowly robbing them of their sight.

Robert Haverly, MD, of Saint Vincent Surgery Center in Erie, Pa., has incorporated the iStent into his practice for glaucoma treatment, according to an Erie Times-News report. The iStent was the ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...

Glaukos Corp. reported 12-month results from the pivotal IDE trial of its Istent Infinite trabecular micro-bypass system, showing substantial reduction in mean diurnal intraocular pressure (IOP) in ...

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...